CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

September 10th 2021

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Dr. Patel on the Integration of CAR T-Cell Therapy in Multiple Myeloma

September 8th 2021

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma

September 3rd 2021

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

P-PSMA-101 Elicits Encouraging Responses in Metastatic Castration-Resistant Prostate Cancer

September 1st 2021

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.

Second-Line Tisagenlecleucel Misses EFS End Point in Aggressive B-cell Non-Hodgkin Lymphoma

August 24th 2021

The CAR T-cell therapy tisagenlecleucel did not significantly improve event-free survival compared with standard of care when used in the second-line treatment of patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12 months of frontline treatment.

Idecabtagene Vicleucel Approved in Europe for Relapsed/Refractory Multiple Myeloma

August 19th 2021

The European Commission has granted a conditional marketing authorization for idecabtagene vicleucel for use in adult patients with relapsed/refractory multiple myeloma who have previously received at least 3 therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody and progressed on their last therapy.

CAR T-Cell Therapy Use Requires Schooling of Adverse Event Recognition and Management

August 13th 2021

Due to the potency of CAR T-cell therapies and the associated adverse events that can to arise in patients receiving this type of treatment, oncology nurses need to be educated on how to best identify and manage these AEs.

Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma

August 13th 2021

Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

Standardized Guidelines Support Management Strategies of CAR T-Cell Therapy–Related Toxicities

August 12th 2021

As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.

Ongoing Research Aims to Solidify CAR T-Cell Therapy’s Place in Non-Hodgkin Lymphoma

August 11th 2021

CAR T-cell therapy has proven to be an effective treatment option in non-Hodgkin lymphoma subtypes, such as diffuse large B-cell lymphoma, and mantle cell lymphoma.

Dr. Park on Selecting Among Available CAR T-Cell Therapies in MCL

August 5th 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Novel Oncolytic Virus/Allogeneic CAR T-Cell Combo Under Development for Solid Tumors

August 4th 2021

The combination of a CF33-CD19 oncolytic virus technology and CyCART-19, is under development for use as a potential therapeutic option for patients with solid tumors.

Dr. Park on Emerging CAR T-Cell Therapies in Hematologic Malignancies

August 3rd 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Emerging Allogeneic CAR T Candidates Usher in a New Era

July 22nd 2021

Dose-dependent engraftment of the investigative CAR T-cell therapy CYAD-211 was demonstrated in the first patient with relapsed/refractory multiple myeloma to receive this dose in the phase 1 IMMUNICY-1 trial, and no graft-versus-host disease has been reported to date.

HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors

July 21st 2021

Repetitive locoregional infusion of HER2-specific CAR T cells did not induce any dose-limiting toxicities.

Dr. Ghia on Key Findings From the CAPTIVATE Trial in CLL

July 19th 2021

Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma

July 14th 2021

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.

Dr. Sperling on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

July 9th 2021

Adam Sperling, MD, PhD, discusses managing CAR T-cell therapy–related toxicities in multiple myeloma.

Ide-Cel Granted Positive EU Opinion for Relapsed/Refractory Multiple Myeloma

June 25th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that idecabtagene vicleucel receive conditional marketing authorization for use in adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and a CD38-targeted antibody, and have progressed on their last therapy.